GlassScriptPhysician profile
Ruba S Odeh
NPI 1578679627
$1,076.89
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $101 · 2021: $44.14 · 2022: $163 · 2023: $12.71 · 2024: $52.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $143.62 | 2019-2024 | |
| Covidien LP | $143.30 | 2019 | |
| Astellas Pharma US INC | $135.88 | 2019-2022 | |
| Philips North America LLC | $123.35 | 2022 | |
| Melinta Therapeutics, LLC | $110.53 | 2019-2024 | Vabomere, Rezzayo, Kimyrsa |
| Merck Sharp & Dohme LLC | $102.66 | 2019-2020 | |
| Allergan, INC. | $85.86 | 2019-2020 | |
| Viiv Healthcare Company | $68.59 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $37.06 | 2019 | |
| Napo Pharmaceuticals INC | $28.61 | 2019 | |
| Emd Serono, INC. | $27.04 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $22.52 | 2019 | |
| Insmed, INC. | $18.00 | 2019 | |
| Janssen Biotech, INC. | $17.16 | 2019 | |
| Abbvie INC. | $12.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruba Odeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.